A Pilot Two-arm, Individual-level, Randomised Controlled Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

Kirby Institute0 sites400 target enrollmentOctober 2022

ConditionsHepatitis C, Chronic

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hepatitis C, Chronic
Sponsor: Kirby Institute
Enrollment: 400
Primary Endpoint: The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an intervention integrating contingency management (financial incentives) to enhance hepatitis C treatment uptake following dried blood spot hepatitis C RNA testing among people with recent injecting drug use attending needle and syringe programs: the AMPLIFY study

Registry

clinicaltrials.gov

Start Date

October 2022

End Date

December 2023

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Kirby Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants have voluntarily signed the informed consent form
•18 years of age or older
•Recent injecting drug use (previous six months)

Exclusion Criteria

•Inability or unwillingness to provide informed consent

Outcomes

Primary Outcomes

The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing

Time Frame: 6 months

Data will be presented in percentages and mean (SD) or median values (interquartile range), as appropriate. Chi square test or Fisher's exact test will be utilised, as appropriate, to examine between group differences.

Secondary Outcomes

Feasibility of recruitment through a peer-based referral incentivization scheme(6 months)
Time to HCV treatment initiation(6 months)
Participant perceptions and acceptability of being involved in a contingency management study will be assessed by study questionnaire(6 months)
Feasibility of a contingency management intervention to enhance hepatitis C treatment uptake(6 months)
Time to HCV treatment completion(6 months)
Time to visit to confirm viral cure (e.g. sustained virological response, SVR12)(6 months)